2023年7月17日

5天改变今天上午01:19分享DIASORIN启动联络®军团菌尿AG测定在所有国家接受退伍军人的CE标志来提高诊断的疾病,一种严重的肺炎军团菌引起的联络®军团菌尿AG测定:是第一个解决方案,涉及到市场允许高通量定性检测嗜肺性军团菌及军团菌LONGBEACHAE抗原;从其他肺部感染军团病歧视与一个简单的测试方法;开发运行在THELIAISON®CLIA分析仪;启动所有国家接受THECE马克。Saluggia, 2023年7月17日- DiaSorin (FTSE MIB: DIA)宣布推出新的联络®军团菌尿抗原Immunodiagnostic试验在所有国家接受CE标志的诊断帮助退伍军人的疾病(LD),危及生命的典型社区获得性肺炎(CAP)。军团菌的物种是一个常见的原因限制在那些人需要住院治疗。误诊和LD不经治疗,通常迅速恶化导致死亡率增加。LD死亡率可能高达40 - 80%未经处理的免疫抑制患者,可以减少到5 - 30%通过适当的识别和病例管理。新的联络®军团菌尿Ag测定提高非典型性肺炎的诊断提供一个精确的军团病的识别。执行的测试是在联络®CLIA分析仪和微生物实验室提供了一种高度自动化的解决方案。 With a simple test method, Legionnaires' disease can be identified in only 35 minutes, allowing timely and targeted antimicrobial treatment. L. pneumophila sg 1 causes from 50 to 80% of Legionnaires' disease cases worldwide. Sg 4 and 6, and the species L. longbeachae, L. micdadei and L. bozemanii are also important in disease, accounting for most of the remaining non-L.pneumophila sg 1 cases of LD. The LIAISON® Legionella Urinary Ag assay with its innovative "dual-antigen" design is able to detect two Legionella's antigens (LPS and PAL) improving sensitivity and specificity. It empowers healthcare professionals to accurately identify Legionella pneumophila and Legionella longbeachae antigens. "The launch of this new assay confirms our ability to position DiaSorin as a specialty player, able to provide innovative solutions with a high medical value" commented Chen Even, Chief Commercial Officer of DiaSorin. "We are confident that our new assay will strongly contribute in discriminating etiological factors in severe atypical pneumonia". About DiaSorin Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 39 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at www.diasoringroup.com